Table 1.

Serum levels of IgA anti-IgG2a RF and IgA-IgG2a IC, and the development of glomerular lesions in BALB/c mice implanted with cells secreting 6-19 IgA or its glycovariants

6-19 IgAIgA Anti-IgG2a (mg/ml)aIgA-IgG2a IC (OD)bGlomerular Lesionsc
WT0.45±0.030.38±0.0410/10
T228P0.88±0.150.51±0.050/12
Tg-10.90±0.160.54±0.080/8
Tg-20.60±0.10NT0/7
Tg-30.53±0.09NT0/7
  • Data are presented as the mean±SEM, unless otherwise indicated. NT, not tested.

  • a Serum levels of IgA anti-IgG2a RF 3 weeks after implantation of 6-19 IgA RF–secreting cells in 2- to 3-month-old BALB/c mice (n=7–12 mice). Serum levels of IgA anti-IgG2a before injection of cells were <0.01 mg/ml.

  • b Serum levels of IgA-IgG2a IC 3 weeks after implantation of 6-19 IgA RF–secreting cells, expressed as OD at 405 nm (n=8–12 mice). Serum levels of IgA-IgG2a IC before injection of cells were 0.07±0.004.

  • c Incidence of glomerular lesions evaluated by histologic examination.